title: Acute myeloid leukemia M4 with bone marrow eosinophilia (M4Eo) and inv(16)(p13q22) exhibits a specific immunophenotype with CD2 expression.
abstract: Extensive immunologic marker analysis was performed to characterize the various leukemic cell populations in eight patients with inv(16)(p13q22) in association with acute myeloid leukemia with abnormal bone marrow eosinophilia (AML-M4Eo). The eight AML cases consisted of heterogeneous cell populations; mainly due to the presence of multiple subpopulations, which varied in size between the patients. However, the immunophenotype of these subpopulations was comparable, independent of their relative sizes. Virtually all AML-M4Eo cells were positive for the pan-myeloid marker CD13. In addition, the AML were partly positive for CD2, CD11b, CD11c, CD14, CD33, CD34, CD36, CDw65, terminal deoxynucleotidyl transferase (TdT), and HLA-DR. Double immunofluorescence stainings demonstrated coexpression of the CD2 antigen and myeloid markers and allowed the recognition of multiple AML subpopulations. The CD2 antigen was expressed by immature AML cells (CD34+, CD14-) and more mature monocytic AML cells (CD34-, CD14+), whereas TdT expression was exclusively found in the CD34+, CD14- cell population. The eight AML-M4Eo cases not only expressed the CD2 antigen, but also its ligand CD58 (leukocyte function antigen-3). Culturing of AML-M4Eo cell samples showed a high spontaneous proliferation in all three patients tested. Addition of a mixture of CD2 antibodies against the T11.1, T11.2, and T11.3 epitopes diminished cell proliferation in two patients with high CD2 expression, but no inhibitory effects were found in the third patient with low frequency and low density of CD2 expression. These results suggest that high expression of the CD2 molecule in AML-M4Eo stimulates proliferation of the leukemic cells, which might explain the high white blood cell count often found in this type of AML.
authors.affiliation: Department of Immunology, University Hospital Dijkzigt/Erasmus University, Rotterdam, The Netherlands.
authors.forename: H J
authors.initials: HJ
authors.lastname: Adriaansen
authors.forename: P A
authors.initials: PA
authors.lastname: te Boekhorst
authors.forename: A M
authors.initials: AM
authors.lastname: Hagemeijer
authors.forename: C E
authors.initials: CE
authors.lastname: van der Schoot
authors.forename: H R
authors.initials: HR
authors.lastname: Delwel
authors.forename: J J
authors.initials: JJ
authors.lastname: van Dongen
mesh_terms: D000293:Adolescent; D000328:Adult; D015703:Antigens, CD / Q000032:analysis; D000945:Antigens, Differentiation, T-Lymphocyte / Q000378:metabolism*; D001853:Bone Marrow / Q000473:pathology; D018801:CD2 Antigens; D002648:Child; D002869:Chromosome Aberrations / Q000473:pathology; D025063:Chromosome Disorders; D007446:Chromosome Inversion; D002885:Chromosomes, Human, Pair 16; D004802:Eosinophilia / Q000235:genetics / Q000276:immunology / Q000473:pathology*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016130:Immunophenotyping; D015479:Leukemia, Myelomonocytic, Acute / Q000235:genetics / Q000276:immunology / Q000473:pathology*; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D011971:Receptors, Immunologic / Q000378:metabolism*
chemical_list: D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D018801:CD2 Antigens; D011971:Receptors, Immunologic